Esketamine nasal spray for the rapid reduction of depressive symptoms in major depressive disorder with acute suicidal ideation or behavior
CM Canuso, DF Ionescu, X Li, X Qiu… - Journal of clinical …, 2021 - journals.lww.com
Purpose/Background: Numerous health authority approvals of esketamine nasal spray,
combined with oral antidepressant, to treat depressive symptoms in adults with major …
combined with oral antidepressant, to treat depressive symptoms in adults with major …
Esketamine nasal spray for rapid reduction of depressive symptoms in patients with major depressive disorder who have active suicide ideation with intent: results of a …
DF Ionescu, DJ Fu, X Qiu, R Lane, P Lim… - International Journal …, 2021 - academic.oup.com
Background Patients with major depressive disorder (MDD) having active suicidal ideation
with intent require immediate treatment. Methods This double-blind study (ASPIRE II) …
with intent require immediate treatment. Methods This double-blind study (ASPIRE II) …
[HTML][HTML] Esketamine nasal spray for rapid reduction of major depressive disorder symptoms in patients who have active suicidal ideation with intent: double-blind …
DJ Fu, DF Ionescu, X Li, R Lane, P Lim… - The Journal of clinical …, 2020 - psychiatrist.com
Objective: To compare esketamine to placebo, each in addition to standard-of-care
treatment, for rapidly reducing major depressive disorder symptoms, including suicidal …
treatment, for rapidly reducing major depressive disorder symptoms, including suicidal …
Esketamine versus placebo on time to remission in major depressive disorder with acute suicidality
DJ Fu, Q Zhang, L Shi, S Borentain, S Guo, M Mathews… - BMC psychiatry, 2023 - Springer
Background Esketamine (ESK) nasal spray, taken with oral antidepressant therapy, is
approved for the treatment of depressive symptoms in adults with major depressive disorder …
approved for the treatment of depressive symptoms in adults with major depressive disorder …
Effect of concomitant benzodiazepine use on efficacy and safety of esketamine nasal spray in patients with major depressive disorder and acute suicidal ideation or …
B Diekamp, S Borentain, DJ Fu, R Murray… - Neuropsychiatric …, 2021 - Taylor & Francis
Purpose The impact of benzodiazepines on the efficacy and safety of esketamine as a rapid-
acting antidepressant remains unclear. Materials and Methods Data from two identically …
acting antidepressant remains unclear. Materials and Methods Data from two identically …
Efficacy and safety of intranasal esketamine for the rapid reduction of symptoms of depression and suicidality in patients at imminent risk for suicide: results of a double …
CM Canuso, JB Singh, M Fedgchin… - FOCUS, A Journal …, 2019 - Am Psychiatric Assoc
Objective: The authors compared the efficacy of standard-of-care treatment plus intranasal
esketamine or placebo for rapid reduction of symptoms of major depression, including …
esketamine or placebo for rapid reduction of symptoms of major depression, including …
Efficacy and safety of fixed-dose esketamine nasal spray combined with a new oral antidepressant in treatment-resistant depression: results of a randomized, double …
M Fedgchin, M Trivedi, EJ Daly… - International Journal …, 2019 - academic.oup.com
Background About one-third of patients with depression fail to achieve remission despite
treatment with multiple antidepressants and are considered to have treatment-resistant …
treatment with multiple antidepressants and are considered to have treatment-resistant …
Efficacy and safety of intranasal esketamine for the rapid reduction of symptoms of depression and suicidality in patients at imminent risk for suicide: results of a double …
CM Canuso, JB Singh, M Fedgchin… - American journal of …, 2018 - Am Psychiatric Assoc
Objective: The authors compared the efficacy of standard-of-care treatment plus intranasal
esketamine or placebo for rapid reduction of symptoms of major depression, including …
esketamine or placebo for rapid reduction of symptoms of major depression, including …
Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: a randomized …
V Popova, EJ Daly, M Trivedi… - American Journal of …, 2019 - Am Psychiatric Assoc
Objective: About one-third of patients with depression fail to achieve remission despite
treatment with multiple antidepressants. This study compared the efficacy and safety of …
treatment with multiple antidepressants. This study compared the efficacy and safety of …
[HTML][HTML] Esketamine nasal spray plus oral antidepressant in patients with treatment-resistant depression: assessment of long-term safety in a phase 3, open-label …
E Wajs, L Aluisio, R Holder, EJ Daly… - The Journal of clinical …, 2020 - psychiatrist.com
Objective: To evaluate long-term safety and efficacy of esketamine nasal spray plus a new
oral antidepressant (OAD) in patients with treatment-resistant depression (TRD). Methods …
oral antidepressant (OAD) in patients with treatment-resistant depression (TRD). Methods …